GCVRZ News and Press, Sanofi Contingent Value Right (Expiring 12/31/2020) From 02/21/24

2024-02-21 07:13:01 ET Regeneron ( NASDAQ: REGN ) and Vertex Pharmaceuticals ( NASDAQ: VRTX ) have crossed $100B in market capitalization for the first time, joining two other giants in the biotech industry, Amgen ( AMGN ) and AbbVie ( ABBV ).... Read the full ...

2024-02-16 10:05:39 ET More on Denali, Sanofi, etc. Sanofi (SNY) Q4 2023 Earnings Call Transcript Sanofi 2023 Q4 - Results - Earnings Call Presentation Sanofi Expands Rare Disease Focus With Inhibrx's INBRX-101 Acquisition Sanofi, Regeneron win Japan approval...

2024-02-08 07:09:07 ET More on AstraZeneca AstraZeneca's Q4 Earnings: Recognizing The Underrated Gem's Growth Why AstraZeneca's Gracell Biotechnologies Acquisition Is A Win-Win AstraZeneca: A $1.1B Shot In The Arm From Icosavax Acquisition AstraZeneca beats t...

2024-02-02 07:13:00 ET More on Regeneron Pharmaceuticals Regeneron Pharmaceuticals Inc. (REGN) 42nd Annual JPMorgan Healthcare Conference - (Transcript) Why I Expect Regeneron To Keep Delivering For Investors In 2024 (Upgrade) Regeneron Pharmaceuticals Inc. (REGN) Am...

2024-02-01 07:55:55 ET More on Sanofi: Sanofi Expands Rare Disease Focus With Inhibrx's INBRX-101 Acquisition Sanofi: Expect A Weak 2024 Leading Up To A Strong 2025 Sanofi incurs loss in Q4 amid generic competition, currency woes Sanofi Non-GAAP EPS of Ȋ...

2024-02-01 01:38:24 ET More on Sanofi Sanofi Expands Rare Disease Focus With Inhibrx's INBRX-101 Acquisition Sanofi: Expect A Weak 2024 Leading Up To A Strong 2025 Sanofi to acquire Inhibrx rare disease asset in $2.2B deal Sanofi on track to snap its six-day ...

2024-01-31 11:34:01 ET More on Teva Pharmaceutical Teva Pharmaceutical Industries Limited (TEVA) Presents at J.P. Morgan 42nd Annual Global Healthcare Conference (Transcript) Teva: 4 Key Drivers For A 2024 Revival (Upgraded Rating) Teva Pharmaceutical Industries Limi...

2024-01-25 14:56:31 ET More on Regeneron Pharmaceuticals Regeneron Pharmaceuticals Inc. (REGN) 42nd Annual JPMorgan Healthcare Conference - (Transcript) Why I Expect Regeneron To Keep Delivering For Investors In 2024 (Upgrade) Regeneron Pharmaceuticals Inc. (REGN) Am...

2024-01-04 13:51:02 ET More on BioNTech, Moderna, etc. Pfizer: If You Missed The Pandemic Entry, Here's Another Chance BioNTech's Strategic Shift: Diversifying Into Cancer Therapeutics The Pfizer Advantage: High Dividend Yield, JN.1 Variant, And Therapeutic Innovatio...

2023-12-14 15:46:45 ET More on AstraZeneca, Sanofi, etc. AstraZeneca: A $1.1B Shot In The Arm From Icosavax Acquisition AstraZeneca Is Feeling The Weight Of The Market In 2023 R&D Day AbbVie, AstraZeneca targeted for improper use of drug patents I...